EuroHeartPath EuroHeartPath: Leading Innovation in Cardiovascular Pathways for Improved Patient Outcomes
- Coordinator
- Universitair Medisch Centrum Utrecht, Netherlands
- Runs
- 1 February 2025 to 31 January 2030
- Status
- Running
- EU funding
- €15.0m
- Total cost
- €26.0m
- Partners
- 35 organisations in 10 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101194785
What the project is doing
In the project's own words, from its summary on CORDIS.
Cardiovascular diseases (CVD) present a significant public health challenge throughout Europe, being the leading cause of morbidity and a major contributor to mortality. Despite technological advancements and preventative strategies, the burden of CVD remains substantial, and the cardiac care pathways across Europe are inadequately mapped. The overarching goal of the EuroHeartPath consortium is to transform cardiovascular care pathways across the continuum of care.
By adopting a pan-European scope and facilitating cross-country comparisons, EuroHeartPath aims to elucidate how care is organized and delivered, providing deeper insights and identifying best practices for integration with the support of stakeholders, including ESC, WONCA, EUPHA, and EPA.EuroHeartPath will simultaneously conduct 18 pathfinder studies to optimize the personalized early detection, diagnosis, monitoring, and treatment of heart failure, atrial fibrillation, ventricular fibrillation, and coronary disease, with a particular emphasis on prevention.
These studies are categorized into four key areas: 1) novel artificial intelligence (AI) and machine learning applications, such as automated AI analysis of ECGs and Holters, and AI for predicting cardiomyopathies and cardiovascular events; 2) digital health integration, aimed at improving the diagnosis of aortic stenosis and enhancing secondary prevention measures; 3) point-of-care testing, including the use of point-of-care diagnostics in primary practice and ambulances to exclude heart failure; and 4) technology and robotics, encompassing robotic echocardiography and invasive diagnostics in obstructive epicardial coronary artery disease.
EuroHeartPath will create a paradigm shift in the management and treatment of heart disease, offering substantial scientific, societal, and economic impacts across the entire patient health journey with a patient centric approach.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Coordinator |
| European Pathway Association | Leuven | Belgium | Participant |
| Insel Gruppe AG | Bern | Switzerland | Associatedpartner |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Deutsches Herzzentrum Munchen | Munich | Germany | Participant |
| Medtronic GmbH | Meerbusch | Germany | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Medtronic Iberica SA | Madrid | Spain | Participant |
| Outcomes'10 SL | Castellón de la Plana | Spain | Participant |
| Servicio Madrileno De Salud | Madrid | Spain | Participant |
| Assistance Publique Hopitaux De Paris | Paris | France | Participant |
| Philips France | Suresnes | France | Participant |
| Rcf@icps | Massy | France | Participant |
| Societe Europeenne De Cardiologie | Biot | France | Participant |
| Amarin Pharmaceuticals Ireland Limited | Dublin | Ireland | Participant |
| Boston Scientific Nederland B.V. | Kerkrade | Netherlands | Participant |
| Chateau Sante | Zeist | Netherlands | Participant |
| Corbotics B.V. | Delft | Netherlands | Participant |
| Cordys Analytics B.V. | Utrecht | Netherlands | Participant |
| European Public Health Association | Utrecht | Netherlands | Participant |
| Heart for Health Ict BV | Amsterdam | Netherlands | Participant |
| Iqvia Solutions B.v. | Amsterdam | Netherlands | Participant |
| Novartis Pharma B.V. | Amsterdam | Netherlands | Participant |
| Philips Medical Systems Nederland BV | Best | Netherlands | Participant |
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Participant |
| Stichting Sionsberg Netwerk Ziekenhuis | Dokkum | Netherlands | Participant |
| Technische Universiteit Eindhoven | Eindhoven | Netherlands | Participant |
| Universiteit Maastricht | Maastricht | Netherlands | Participant |
| Van Vliet Diagnostics BV | Almere | Netherlands | Participant |
| Viduet Health BV | Bunnik | Netherlands | Participant |
| Vintura BV | Utrecht | Netherlands | Participant |
| Stichting Wonca Europe | Ljubljana | Slovenia | Participant |
| Astrazeneca UK Limited | Cambridge | United Kingdom | Participant |
| London School of Economics and Political Science | London | United Kingdom | Participant |
| Zeesta Labs | London | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI